Clinical Trial Update: Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis [Phase 2]

View source ↗

Summary

Clinical trial update on DS-8201a (trastuzumab deruxtecan) for advanced breast cancer, including biomarker analyses, in a Phase 2 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: UNICANCER | Conditions: Breast Tumors | Phase 2 | Status: COMPLETED